公开(公告)号：US20230050031A1

公开(公告)日：2023-02-16

申请号：US17833941

申请日：2022-06-07

Applicant: THE JOHNS HOPKINS UNIVERSITY ,  BRISTOL-MYERS SQUIBB COMPANY

Inventor： Honggang Cui ,  Yi Li ,  Xuankuo Xu ,  Lye Lin Lock ,  Zhengjian Li

IPC: C07K16/06 ,  B01D15/38 ,  B01J20/24 ,  B01J20/28

Abstract: In certain embodiments, the present invention provides novel antibody purification methods and systems using a potentially simple and cost-efficient means. In some embodiments, customized Z-33 derived from Staphylococcus aureus Protein A is used to construct immuno-amphiphile molecules which can assemble into immunofibers in aqueous solution with bioactive epitopes on the surface and have IgG binding ability.

公开(公告)号：US20230045357A1

公开(公告)日：2023-02-09

申请号：US17861809

申请日：2022-07-11

Applicant: Université de Montréal ,  Bristol-Myers Squibb Company

Inventor： Eldon Scott PRIESTLEY ,  Samuel Kaye REZNIK ,  Edward H. RUEDIGER ,  James R. GILLARD ,  Oz Scott HALPERN ,  Wen JIANG ,  Jeremy RICHTER ,  Rejean RUEL ,  Sasmita TRIPATHY ,  Wu YANG ,  Xiaojun ZHANG

IPC: C07D401/14 ,  C07D401/10 ,  C07D235/26 ,  C07D403/10 ,  C07D403/14 ,  C07D413/10 ,  C07D471/04 ,  C07D257/04 ,  C07D417/14 ,  C07D405/14 ,  C07D233/90 ,  C07D498/10 ,  C07D413/14 ,  A61P9/04 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  C07D239/20 ,  C07D271/07

Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.

公开(公告)号：US11572405B2

公开(公告)日：2023-02-07

申请号：US16768838

申请日：2019-01-11

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Michael Carleton ,  David Feltquate ,  Olivier De Henau ,  Timothy Patrick Reilly ,  Tian Chen ,  Ye Feng ,  Shu-Pang Ben Huang ,  Ming Zhou ,  Ramachandran Suresh

IPC: C07K16/24 ,  A61P35/04 ,  A61P35/00 ,  A61K39/395 ,  C07K16/28 ,  G01N33/68 ,  A61K39/00

Abstract: Provided herein are methods for the clinical treatment of tumors (e.g., advanced solid tumors) in patients having certain levels of serum IL-8 using an anti-IL-8 antibody in combination with an anti-PD-1 antibody.

公开(公告)号：US20230025648A1

公开(公告)日：2023-01-26

申请号：US17779104

申请日：2020-11-23

Applicant: Bristol-Myers Squibb Company

Inventor： Letha CHEMMALIL ,  Julia DING ,  Zhengjian LI

IPC: G01N33/68

Abstract: This disclosure provides a novel label-free N-glycan analysis method to detect and quantify N-glycans and N-linked glycosylation profiles without using a label, such as a fluorescent label. This method allows for reduced sample preparation and chromatographic separation times, and can be used for product batch release.

公开(公告)号：US20230020273A1

公开(公告)日：2023-01-19

申请号：US17289269

申请日：2019-10-28

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Steven H. Spergel ,  William J. Pitts ,  Michael E. Mertzman ,  Ryan M. Moslin ,  Trevor C. Sherwood ,  John L. Gilmore ,  Alaric J. Dyckman

IPC: C07D413/14 ,  C07B59/00 ,  C07D403/12 ,  C07D413/12 ,  C07D417/14 ,  C07D417/12 ,  C07D401/14 ,  C07D403/14

Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

公开(公告)号：US20230018980A1

公开(公告)日：2023-01-19

申请号：US17942217

申请日：2022-09-12

Applicant: Bristol-Myers Squibb Company ,  Ayala Pharmaceuticals Inc.

Inventor： Bruce S. FISCHER ,  Gaurav Bajaj ,  Matti Davis ,  Joel Kaye

IPC: A61K31/5513 ,  A61K9/00 ,  A61P35/00

Abstract: The present invention provides compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof; optionally in combination with an additional cancer therapeutic agent, and methods of use thereof for treating proliferative diseases and disorders such as Desmoid tumors.

公开(公告)号：US20230000822A1

公开(公告)日：2023-01-05

申请号：US17779328

申请日：2020-11-24

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Dennis Michael Grasela

IPC: A61K31/404 ,  A61K9/00 ,  C07K16/28

Abstract: Disclosed is method of treating a patient having rheumatoid arthritis, comprising administering sequentially to said patient, a therapeutically effective dose of branebrutinib for a first period, followed by a therapeutically effect dose of abatacept for a second period.

公开(公告)号：US20220411384A1

公开(公告)日：2022-12-29

申请号：US17743557

申请日：2022-05-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Steven H. Spergel ,  Ryan M. Moslin ,  Michael Edward Mertzman ,  Joseph A. Tino ,  Shoshana L. Posy ,  Sirish Kaushik Lakkaraju ,  Zili Xiao ,  James Kempson

IPC: C07D249/04 ,  A61P25/16 ,  A61K31/501 ,  A61P25/28

Abstract: There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.

公开(公告)号：US20220389110A1

公开(公告)日：2022-12-08

申请号：US17662034

申请日：2022-05-04

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Maria JURE-KUNKEL ,  Paul GAGNIER ,  David FELTQUATE

IPC: C07K16/28 ,  A61K39/395 ,  A61K31/404 ,  A61K45/06 ,  A61K31/506 ,  A61K31/44

Abstract: This disclosure provides a method for treating a subject afflicted with a renal cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent. The other anti-cancer agent may be an anti-angiogenic tyrosine kinase inhibitor or an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody. The disclosure also provides a kit for treating a subject afflicted with a renal cancer, the kit comprising a dosage of an anti-PD-1 antibody, a dosage of another anti-cancer agent which is an anti-angiogenic tyrosine kinase inhibitor or an anti-CTLA-4 antibody, and instructions for using the anti-PD-1 antibody and the other anti-cancer agent in any of the disclosed methods for treating a renal cancer.

公开(公告)号：US20220380335A1

公开(公告)日：2022-12-01

申请号：US17274220

申请日：2019-09-12

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Junqing Guo ,  Jie Chen ,  Carolyn Diane Dzierba ,  Amy C. Hart ,  Guanglin Luo ,  John E. Macor ,  Willian J. Pitts ,  Sing-Yuen Sit

IPC: C07D401/04 ,  C07D401/14 ,  C07D405/14

Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.